{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:43:12Z","timestamp":1781664192248,"version":"3.54.5"},"reference-count":34,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","award":["2022, 6231-335-210-01"],"award-info":[{"award-number":["2022, 6231-335-210-01"]}],"id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Postinfectious autoimmunity is a hallmark of Guillain-Barr\u00e9 syndrome (GBS), and GBS incidence closely parallels that of its immune triggers. Sociobehavioural interventions implemented during the COVID-19 pandemic have altered the infectious disease landscape.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This nationwide time-series correlation study analysed GBS incidence, sentinel surveillance and SARS-CoV-2 vaccination data from January 2017 to December 2021 in the National Health Insurance Service and Korean Disease Control and Prevention Agency databases. The incidence of GBS and sentinel gastrointestinal and respiratory infectious diseases during the pandemic (2020\u20132021) was estimated and compared with both prepandemic (2017\u20132019) and incidence predicted in a time-series forecasting model. Time-series correlation analysis was used to examine the temporal association between GBS, infectious triggers and SARS-CoV-2 vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the pandemic, the total crude cumulative incidence rate was 2.1 per 100\u2009000 population, which is lower than the prepandemic incidence, especially in age groups of less than 60 years. Seasonality was briefly interrupted during the winter of 2021. The majority of respiratory and some gastrointestinal conditions had a lower-than-expected incidence during the pandemic. Compared with the prepandemic state, during the pandemic period a higher number of gastrointestinal pathogens (<jats:italic>Escherichia coli<\/jats:italic>, <jats:italic>Campylobacter<\/jats:italic> spp.<jats:italic>, Clostridium perfringens, Yersinia enterocolitica<\/jats:italic> and enteric adenovirus) had significant, moderate-to-strong positive temporal associations with GBS. The temporal association between SARS-CoV-2 infection and GBS was not significant, but SARS-CoV-2 vaccination exhibited a strong positive temporal association with GBS in 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The incidence of GBS and sentinel infectious diseases decreased to below-expected levels during the pandemic, with the former attributable to the decreased incidence of non-COVID-19 respiratory and gastrointestinal infections. The evolving incidence of autoimmune postinfectious phenomena following the pandemic needs attention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2022-000378","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T11:55:11Z","timestamp":1672401311000},"page":"e000378","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Deciphering changes in the incidence of the Guillain-Barr\u00e9 syndrome during the COVID-19 pandemic: a nationwide time-series correlation study"],"prefix":"10.1136","volume":"4","author":[{"given":"Hyunju","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju, Chungcheongbuk-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namwoo","family":"Heo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Yongin Severance Hospital, Yongin, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyok","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju, Chungcheongbuk-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-7650","authenticated-orcid":false,"given":"Jongmok","family":"Ha","sequence":"additional","affiliation":[{"name":"Infectious Disease Control Center, Gyeonggi Provincial Government, Suwon, Gyeonggi-do, Korea"},{"name":"Department of Neurology, Yeoncheon-gun Health Medical center, Yeoncheon-gun, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"2025072811484796000_4.2.e000378.1","unstructured":"World Health Organization . Who COVID-19 Dashboard. Geneva: World Health Organization, 2020. https:\/\/covid19.who.int\/"},{"key":"2025072811484796000_4.2.e000378.2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"2025072811484796000_4.2.e000378.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain-Barr\u00e9 syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J Neuroinflammation"},{"key":"2025072811484796000_4.2.e000378.4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000430917","article-title":"A 15-year nationwide epidemiological analysis of Guillain-Barr\u00e9 syndrome in Taiwan","volume":"44","author":"Huang","year":"2015","journal-title":"Neuroepidemiology"},{"key":"2025072811484796000_4.2.e000378.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2007.00153.x"},{"key":"2025072811484796000_4.2.e000378.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314310"},{"key":"2025072811484796000_4.2.e000378.7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.nrl.2020.07.004","article-title":"Relation between COVID-19 and Guillain-Barr\u00e9 syndrome in adults. systematic review","volume":"35","author":"Trujillo Gittermann","year":"2020","journal-title":"Neurologia"},{"key":"2025072811484796000_4.2.e000378.8","doi-asserted-by":"publisher","DOI":"10.3201\/eid1201.050965"},{"key":"2025072811484796000_4.2.e000378.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2004.00799.x"},{"key":"2025072811484796000_4.2.e000378.10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3988\/jcn.2022.18.1.48","article-title":"Incidence, disability, and mortality in patients with Guillain-Barr\u00e9 syndrome in Korea: a nationwide population-based study","volume":"18","author":"Yi","year":"2022","journal-title":"J Clin Neurol"},{"key":"2025072811484796000_4.2.e000378.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309056"},{"key":"2025072811484796000_4.2.e000378.12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jmv.27321","article-title":"Fewer non\u2010COVID\u201019 respiratory tract infections and gastrointestinal infections during the COVID\u201019 pandemic","volume":"94","author":"Tanislav","year":"2022","journal-title":"J Med Virol"},{"key":"2025072811484796000_4.2.e000378.13","first-page":"1","article-title":"Statistical methods in cancer research. Volume II--The design and analysis of cohort studies","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"2025072811484796000_4.2.e000378.14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2307\/2348687","article-title":"Holt-Winters forecasting: some practical issues","volume":"37","author":"Chatfield","year":"1988","journal-title":"The Statistician"},{"key":"2025072811484796000_4.2.e000378.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.beth.2006.05.002"},{"key":"2025072811484796000_4.2.e000378.16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijforecast.2003.09.015","article-title":"Forecasting seasonals and trends by exponentially weighted moving averages","volume":"20","author":"Charles","year":"2004","journal-title":"International Journal of Forecasting"},{"key":"2025072811484796000_4.2.e000378.17","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.6.3.324"},{"key":"2025072811484796000_4.2.e000378.18","doi-asserted-by":"publisher","DOI":"10.1159\/000324710"},{"key":"2025072811484796000_4.2.e000378.19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jns.12239","article-title":"Epidemiology of Guillain-Barr\u00e9 syndrome in Finland 2004-2014","volume":"22","author":"Sipil\u00e4","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"2025072811484796000_4.2.e000378.20","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1111\/ene.14860","article-title":"Prevalence, clinical characteristics and outcomes of Guillain\u2212Barr\u00e9 syndrome spectrum associated with COVID\u201019: a systematic review and meta\u2010analysis","volume":"28","author":"Palaiodimou","year":"2021","journal-title":"Eur J Neurol"},{"key":"2025072811484796000_4.2.e000378.21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"2025072811484796000_4.2.e000378.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88309-1","article-title":"COVID-19 non-pharmaceutical intervention portfolio effectiveness and risk communication predominance","volume":"11","author":"Chan","year":"2021","journal-title":"Sci Rep"},{"key":"2025072811484796000_4.2.e000378.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01872-8","article-title":"The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories","volume":"19","author":"Liu","year":"2021","journal-title":"BMC Med"},{"key":"2025072811484796000_4.2.e000378.24","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.124610"},{"key":"2025072811484796000_4.2.e000378.25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajem.2021.01.065","article-title":"The impact of COVID-19 lockdown on infectious diseases epidemiology: the experience of a tertiary Italian pediatric emergency department","volume":"43","author":"Rotulo","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2025072811484796000_4.2.e000378.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"key":"2025072811484796000_4.2.e000378.27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir960"},{"key":"2025072811484796000_4.2.e000378.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit222"},{"key":"2025072811484796000_4.2.e000378.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.005"},{"key":"2025072811484796000_4.2.e000378.30","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1016\/j.vaccine.2007.03.053","article-title":"Guillain-Barre syndrome after vaccination in United States a report from the CDC\/FDA vaccine adverse event reporting system","volume":"25","author":"Souayah","year":"2007","journal-title":"Vaccine"},{"key":"2025072811484796000_4.2.e000378.31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10654-019-00596-1","article-title":"Vaccines and the risk of Guillain-Barr\u00e9 syndrome","volume":"35","author":"Chen","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2025072811484796000_4.2.e000378.32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the vaccine safety Datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025072811484796000_4.2.e000378.33","article-title":"COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: analyses using the National immunoglobulin database","author":"Keh","year":"2022","journal-title":"Brain"},{"key":"2025072811484796000_4.2.e000378.34","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2013.811119"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2022-000378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:48:55Z","timestamp":1753728535000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2022-000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,30]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bmjno-2022-000378"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2022-000378","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}